Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration

被引:35
作者
Wallis, SC
Mullany, DV
Lipman, J
Rickard, CM
Daley, PJ
机构
[1] Univ Queensland, Div Anaesthesiol & Crit Care, Brisbane, Qld, Australia
[2] Univ Queensland, Royal Brisbane Hosp, Intens Care Facil, Herston, Qld 4029, Australia
[3] Prince Charles Hosp, Intens Care Unit, Brisbane, Qld, Australia
关键词
antibiotics; ciprofloxacin; pharmacokinetics; continuous renal replacement therapy; sepsis;
D O I
10.1007/s001340100857
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: To investigate the pharmacokinetics of intravenous ciprofloxacin 200 mg every 8 h in critically ill patients on continuous veno-venous haemodiafiltration (CVVHDF), one form of continuous renal replacement therapy (CRRT). Design and setting: Open, prospective clinical study in a multidisciplinary, intensive care unit in a university-affiliated tertiary referral hospital. Patients: Sis critically ill patients with acute renal failure on CVVHDF. Interventions: Timed blood and ultrafiltrate samples were collected to allow pharmacokinetics and clearances to be calculated of initial and subsequent doses of 200 mg intravenous ciprofloxacin. CVVHD was performed with 1 l/h of dialysate and 2 l/h of predilution filtration solution, producing 3 lih of dialysis effluent. The blood was pumped at 200 ml/min using a Gambro BMM-10 blood pump through a Hospal AN69HF haemofilter,. Measurements and results: Ten pharmacokinetic profiles were measured. The CVVHDF displayed a urea clearance of 42 +/- 3 ml/min, and removed ciprofloxacin with a clearance of 37 +/- 7 ml/min. This rate was 2-2.5 greater than previously published for ciprofloxacin in other forms of CRRT. On average the CVVHDF was responsible for clearing a fifth of all ciprofloxacin eliminated (21 +/- 10%). The total body clearance of ciprofloxacin was 12.2 +/- 4.3 l/h. The trough concentration following the initial dose was 0.7 +/- 0.3 mg/l. The area under the plasma concentration time curves over a 24-h period ranged from 21 to 55 mg .h l(-1). Conclusions: Intravenous ciprofloxacin 600 mg/day in critically ill patients using this form of CRRT produced adequate plasma levels for many resistant microbes found in intensive care units.
引用
收藏
页码:665 / 672
页数:8
相关论文
共 29 条
[1]   CIPROFLOXACIN LEVELS IN A PATIENT UNDERGOING VENOVENOUS HEMODIAFILTRATION [J].
BARRIE, JR ;
MOUSDALE, S .
INTENSIVE CARE MEDICINE, 1992, 18 (07) :437-438
[2]   THE PHARMACOKINETICS OF CIPROFLOXACIN IN PATIENTS WITH IMPAIRED RENAL-FUNCTION [J].
BOELAERT, J ;
VALCKE, Y ;
SCHURGERS, M ;
DANEELS, R ;
ROSSENEU, M ;
ROSSEEL, MT ;
BOGAERT, MG .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 16 (01) :87-93
[3]  
BONORDEN PR, 1993, CLIN PHARMACOKINET, V24, P362
[4]   CLINICAL PHARMACOKINETICS DURING CONTINUOUS HEMOFILTRATION [J].
BRESSOLLE, F ;
KINOWSKI, JM ;
DELACOUSSAYE, JE ;
WYNN, N ;
ELEDJAM, JJ ;
GALTIER, M .
CLINICAL PHARMACOKINETICS, 1994, 26 (06) :457-471
[5]   ANTIMICROBIAL PRESCRIBING IN PATIENTS ON HEMOFILTRATION [J].
COTTERILL, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (05) :773-780
[6]  
DAVIES SP, 1992, NEPHROL DIAL TRANSPL, V7, P848
[7]   Ciprofloxacin - An updated review of its pharmacology, therapeutic efficacy and tolerability [J].
Davis, R ;
Markham, A ;
Balfour, JA .
DRUGS, 1996, 51 (06) :1019-1074
[8]  
FISH DN, 1995, PHARMACOTHERAPY, V15, P236
[9]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[10]   PHARMACOKINETICS OF CIPROFLOXACIN AFTER ORAL AND PARENTERAL ADMINISTRATION [J].
HOFFKEN, G ;
LODE, H ;
PRINZING, C ;
BORNER, K ;
KOEPPE, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (03) :375-379